R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services comprising physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was incorporated in 2003 and is headquartered in Chicago, Illinois.

Overall MarketRank^™

1.80 out of 5 stars

Finance Sector

339th out of 1,951 stocks

Management Services Industry

2nd out of 12 stocks

2.5 Analyst's Opinion

Consensus Rating
R1 RCM has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.60, R1 RCM has a forecasted upside of 14.2% from its current price of $25.05.
Amount of Analyst Coverage
R1 RCM has only been the subject of 1 research reports in the past 90 days.

2.1 Community Rank

Outperform Votes
R1 RCM has received 228 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
R1 RCM has received 326 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
R1 RCM has received 58.84% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote “Outperform” if you believe RCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
R1 RCM does not currently pay a dividend.
Dividend Growth
R1 RCM does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, R1 RCM insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,056,071.00 in company stock.
Percentage Held by Insiders
59.40% of the stock of R1 RCM is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
81.16% of the stock of R1 RCM is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for R1 RCM are expected to grow by 160.00% in the coming year, from $0.25 to $0.65 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of R1 RCM is 278.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of R1 RCM is 278.36, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 23.26.
Price to Earnings Growth Ratio
R1 RCM has a PEG Ratio of 4.00. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
R1 RCM has a P/B Ratio of 156.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

R1 RCM (NASDAQ:RCM) Frequently Asked Questions

Is R1 RCM a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" R1 RCM stock.
View analyst ratings for R1 RCM or view top-rated stocks.

What stocks does MarketBeat like better than R1 RCM?

Wall Street analysts have given R1 RCM a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but R1 RCM wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for R1 RCM.

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) announced its earnings results on Tuesday, May, 4th. The healthcare provider reported ($2.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.08 by $2.45. The healthcare provider earned $342.60 million during the quarter, compared to analyst estimates of $338.74 million. R1 RCM had a net margin of 3.69% and a trailing twelve-month return on equity of 117.07%. R1 RCM's revenue for the quarter was up 6.9% on a year-over-year basis. During the same period last year, the firm posted $0.05 earnings per share.
View R1 RCM's earnings history.

How has R1 RCM's stock price been impacted by COVID-19?

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RCM shares have increased by 146.6% and is now trading at $25.05.
View which stocks have been most impacted by COVID-19.

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.41 billion-$1.46 billion, compared to the consensus revenue estimate of $1.45 billion.

What price target have analysts set for RCM?

5 brokers have issued 1-year target prices for R1 RCM's shares. Their forecasts range from $22.00 to $35.00. On average, they anticipate R1 RCM's share price to reach $28.60 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts' price targets for R1 RCM or view top-rated stocks among Wall Street analysts.

Who are R1 RCM's key executives?

R1 RCM's management team includes the following people:

Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 50, Pay $1.05M)
Ms. Rachel Wilson, Exec. VP, CFO & Treasurer (Age 48, Pay $349.68k) (LinkedIn Profile)
Mr. Richard B. Evans Jr., Sr. VP, Corp. Controller & Chief Accounting Officer (Age 53, Pay $393.27k)
Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 50, Pay $692.74k) (LinkedIn Profile)
Mr. John M. Sparby, Exec. VP of Operations & Delivery and COO (Age 45) (LinkedIn Profile)
Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.
Mr. Corey Perman, Exec. VP of Compliance & Risk (LinkedIn Profile)
Mr. Sean Radcliffe, Exec. VP, Gen. Counsel & Corp. Sec. (LinkedIn Profile)
Mr. Vijay Kumar Kotte, Exec. VP of Strategy & Corp. Devel. and Chief Solutions Officer (Age 43) (LinkedIn Profile)
Ms. Kate Sanderson, Exec. VP & Chief HR Officer (LinkedIn Profile)

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM CEO Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among R1 RCM's employees.

Who are some of R1 RCM's key competitors?

Some companies that are related to R1 RCM include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of RCM's competitors.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology Group (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.52%), Paradigm Capital Management Inc. NY (1.47%), BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp (0.29%), Congress Asset Management Co. MA (0.14%), Rhumbline Advisers (0.13%) and Mckinley Capital Management LLC Delaware (0.11%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli, Charles J Ditkoff, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan and Michael C Feiner.
View institutional ownership trends for R1 RCM.

Which institutional investors are selling R1 RCM stock?

RCM stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Mckinley Capital Management LLC Delaware, M&T Bank Corp, Victory Capital Management Inc., Congress Asset Management Co. MA, The PNC Financial Services Group Inc., Robertson Stephens Wealth Management LLC, and Alliancebernstein L.P.. Company insiders that have sold R1 RCM company stock in the last year include Gary Steven Long, John M Sparby, and Michael C Feiner.
View insider buying and selling activity for R1 RCM or view top insider-selling stocks.

Which institutional investors are buying R1 RCM stock?

RCM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Compagnie Lombard Odier SCmA, Strs Ohio, James Investment Research Inc., Everence Capital Management Inc., Rhumbline Advisers, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, and New York State Teachers Retirement System. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan.
View insider buying and selling activity for R1 RCM or or view top insider-buying stocks.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $25.05.

How much money does R1 RCM make?

R1 RCM has a market capitalization of $6.55 billion and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does R1 RCM have?

R1 RCM employs 19,000 workers across the globe.

Does R1 RCM have any subsidiaries?

The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Advanced Data Processing Inc., Cerner RevWorks, Intermedix, Intermedix ARM LLC, Intermedix Analytics LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Physician Services LLC, Intermedix Staffing Inc., Med Media Inc., Medical Consultants Inc., Optima (NZ) Limited, Optima (US) LTD, Practice Support Resources LLC, Project Links Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCI Solutions, The DeZonia Group Inc., The Optima Corporation (International) LTD, The Optima Corporation Limited, and The Optima Corporation PTY LTD.

When was R1 RCM founded?

R1 RCM was founded in 2003.

What is R1 RCM's official website?

The official website for R1 RCM is www.r1rcm.com.

Where are R1 RCM's headquarters?

R1 RCM is headquartered at 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at (312) 324-7820 or via email at [email protected]

This page was last updated on 5/8/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

R1 RCM Stock Forecast, Price & News

Adding

Adding

Adding R1 RCM Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links

Headlines

About R1 RCM

MarketRank™

Overall MarketRank™